Trexquant Investment LP Reduces Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Trexquant Investment LP lessened its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 15.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 120,065 shares of the company's stock after selling 22,576 shares during the quarter. Trexquant Investment LP owned approximately 0.15% of Viridian Therapeutics worth $2,302,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth about $26,000. AlphaQuest LLC increased its stake in Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after buying an additional 1,519 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Viridian Therapeutics by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock valued at $318,000 after acquiring an additional 2,036 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Viridian Therapeutics by 19.5% in the fourth quarter. Arizona State Retirement System now owns 16,596 shares of the company's stock valued at $318,000 after acquiring an additional 2,708 shares in the last quarter. Finally, Corebridge Financial Inc. boosted its stake in shares of Viridian Therapeutics by 8.6% in the fourth quarter. Corebridge Financial Inc. now owns 36,336 shares of the company's stock worth $697,000 after acquiring an additional 2,878 shares during the last quarter.

Viridian Therapeutics Trading Up 5.3 %

NASDAQ:VRDN traded up $0.61 on Friday, reaching $12.02. The company's stock had a trading volume of 1,208,187 shares, compared to its average volume of 1,192,474. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The stock has a 50 day moving average price of $15.08 and a 200 day moving average price of $18.94. The firm has a market cap of $979.45 million, a price-to-earnings ratio of -2.79 and a beta of 0.81. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, equities analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on VRDN shares. Wells Fargo & Company restated an "equal weight" rating and issued a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. HC Wainwright restated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Finally, Royal Bank of Canada boosted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.